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Abstract
Background: Autosomal dominant spinocerebellar ataxia type 1 is an adult onset progressive disorder with well
characterized neurodegeneration in the cerebellum and brainstem. Beyond brain atrophy, few data exist concerning retinal
and optic nerve involvement.
Objective: To evaluate retinal changes in SCA1 patients compared to age and gender matched healthy controls.
Methodology/Principal Findings: Nine patients with SCA1 were prospectively recruited from the ataxia clinic and were
compared to nine age and gender matched healthy controls. Both cohorts received assessment of visually evoked
potentials and eye examination by optical coherence tomography to determine retinal nerve fiber layer thickness and total
macular volume. While no differences were found in visually evoked potentials, SCA1 patients showed a significant
reduction of mean retinal nerve fiber layer thickness (RNFLT) compared to healthy controls (84613 mm vs. 9768 mm,
p= 0.004). Temporal areas showed the most prominent RNFLT reduction with high statistical significances (temporal-
inferior: p,0.001, temporal: p,0.001, temporal-superior: p = 0.005) whereas RNFLT in nasal areas was in the range of the
control group. From six SCA1 patients an additional macular scan was obtained. The comparison to the corresponding
healthy control showed a slight but not significant reduction in TMV (8.2260.68 mm3 vs. 8.6160.41 mm3, p = 0.15).
Conclusion: In SCA1 patients, we found evidence for degeneration of retinal nerve fibers. The temporal focus of the
observed retinal nerve fiber layer reduction suggests an involvement of the papillo-macular bundle which resembles
pathology found in toxic or mitochondrial optic nerve disease such as Leber’s hereditary optic neuropathy (LHON) or
dominant optic atrophy (DOA).
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Introduction
Spinocerebellar ataxia type 1 (SCA1) is an autosomal-
dominantly inherited, late-onset neurodegenerative disease pri-
marily affecting the cerebellar cortex and brainstem. Affected
patients suffer from disturbed motor coordination, slurred speech,
dysphagia, spasticity, extrapyramidal movements such as dystonia
or chorea, cerebellar oculomotor disturbances and ophthalmopar-
esis, saccade slowing and - at late disease stage - cognitive
impairment [1]. A gain-of-function toxicity of the ataxin 1 protein
was identified as the main causative agent in SCA1: In the
ATXN1 gene on chromosome 6p23 a CAG-repeat expansion of
variable length reaching between 39 and 83 repeats encodes for a
prolonged polyglutamine chain in ataxin1 protein [2]. The
physiologic function of ataxin1 is barely understood [3].
Subsequent nuclear and cytosolic protein aggregation in cerebellar
Purkinje cells and brainstem neurons finally leads to cell death.
Patients with longer CAG repeat tend to have an earlier disease
onset and a faster progression than patients with short repeat
expansions, causing great variations in disease severity even within
families [1].
Historically the classification of spinocerebellar ataxias has been
directed by additional extracerebellar sign presence (autosomal
dominant ataxia type I, ADCA I) or absence (ADCAIII), with
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cerebellar ataxia plus retinal degeneration being termed ADCA II
[4]. Since genetic testing became available, at least 30 spinocer-
ebellar ataxia subtypes have been identified with different gene
localisation. SCA1 belongs to ADCA I group without known
retinal involvement, whereas in SCA7 (ADCA II) degeneration of
macula or retina is well established [5][6]. In SCA1 patients,
however, some groups found ophthalmologic pathology besides
well described cerebellar oculomotor abnormalities: Visual acuity
reduction with color vision failure and visual field contraction are
reported. Some case collections suggest an increase of these
symptoms with disease duration [7][8], but do not find prominent
changes at disease onset [8]. Electroretinogram (ERG) is reported
to show mild attenuation of oscillatory potentials and corneal
endothelial cell density was reported decreased [8]. The reduced
visual acuity in SCA1 has been attributed to optic atrophy, which
was first described by fundus examination [8]. Optic nerve
involvement was also suggested by a significant percentage of VEP
abnormalities in SCA1 patients [9][10]. However in these studies
40–50% of SCA1 patients did not show VEP alteration and earlier
neuro-pathologic work could not establish retinal or optic nerve
pathology in SCA1 [11]. In summary, descriptions on retinal and
optic nerve changes in SCA1 are controversial and no data exists
on retinal pathology using high resolution OCT so far.
Optical coherence tomography (OCT) is a modern non-invasive
method for high-resolution retinal investigations. The recently
developed spectral domain technique allows spatial resolution
down to 3 mm when measuring retinal nerve fiber layer thickness
(RNFLT), which has previously only been possible with histopa-
thology and ranges far above MRI resolution [12]. OCT has
become a powerful tool in ophthalmologic diagnostics of diseases
affecting retinal tissue e.g. glaucoma [12] or multiple sclerosis
[13][14]. Since it allows unique morphologic characterization of
neuronal cells belonging to the CNS, the method is currently
explored for diagnosis and monitoring of disease progression in a
variety of neurodegenerative disorders as a surrogate parameter
for cerebral and/or optic nerve axonal loss [15][16][17].
Due to its simple application even in severely handicapped
individuals the method is well suited for examination of ataxia
patients. It has so far been applied in SCA7, where a significant
reduction in RNFLT in all quadrants sparing the temporal one is
consistently found [6][5]. To the best of our knowledge in other
forms of SCA no systematic study of retinal involvement using
OCT has been performed so far.
Against this background, we set out to examine individuals with
genetically proven SCA1 compared to age-and-gender matched
healthy controls with OCT and VEP for retinal and optic nerve
involvement.
Methods
Ethics statement
The study was approved by the institutional ethics committee
and all participants gave informed written consent.
Objectives
To evaluate retinal changes in SCA1 patients compared to age
and gender matched healthy controls.
Participants
Patients were recruited from the ataxia outpatient clinic of the
Charite´ university hospital in Berlin from December 2009 to January
2011. Inclusion criteria were a genetically diagnosed SCA1 and age
ranging from 18 to 75 years. Healthy controls were matched by
gender and age with a tolerance of63 years. Participants with known
pre-existing ophthalmological diseases were excluded.
If available, patients provided data of the number of CAG
repeats in the ATXN1 gene, which were genetically ascertained by
external laboratories. The disease duration was defined as the time
(in years) since the first symptom appeared. Visual Acuity (VA) was
assessed using Snellen Charts and refractive error (REF) was
estimated using the Heidelberg Spectralis integrated confocal
scanning laser ophthalmoscope (SLO).
Clinical examination
The SARA score was used for assessment and rating of patients’
ataxia [18]. Briefly, the test assesses the following functions: gait,
stance, sitting, speech disturbance, finger chase, nose-finger test,
fast alternating hand movements and heel-shin slide. A summary
score of these functional items gives the final SARA score, with a
range from 0 (no ataxia) to 40 (most severe ataxia).
Optical Coherence Tomography
A spectral domain OCT device (Heidelberg Spectralis SD-
OCT, Heidelberg Engineering, Germany, Spectralis software
version 5.2.4.0, Eye Explorer Software 1.6.2.0) was used to
measure the RNFLT and the total macular volume (TMV). For
RNFLT, three 3.4 mm circular scans were acquired using the
standard protocol and the scan with the highest quality value was
chosen (in case of equal quality, an arbitrary scan was taken). The
thickness between the inner limiting membrane and the retinal
nerve fiber layer was calculated by the device software’s
segmentation algorithm. As parameters we used the average
RNFLT of the full circle scan (G) and the partition of the circle in
the following sectors: nasal-superior (NS), nasal (N), nasal-inferior
(NI), temporal-inferior (TI), temporal (T) and temporal-superior
(TS). The partition is visualized in figure 1C.
For the analysis of further retinal tissue layers, the program
OCTseg [19] was used for automatic layer segmentation. Each
segmentation result was manually corrected in a blinded fashion and
the exported segmentation lines were used to calculate the thicknesses
of the following layers: ganglion cell layer (GCL) and inner plexiform
layer (IPL), inner nuclear layer (INL) and outer plexiform layer
(OPL), outer nuclear layer (ONL) and photoreceptor layer (PRL) and
the retinal pigment epithelium (RPE) (figure 2A). The RNFL
segmentation of OCTseg confirmed the previous results.
The TMV was appointed by a custom protocol which generated
61 slices (B-scans) focusing the fovea centralis with a scanning angle
of 30u625u and a resolution of 768 A-scans per B-scan. Some
patients were not able to focus the fixation point during examination
due to strong eye and head movement. TMV was calculated by
estimating the distance between the inner limiting membrane and
the Bruch-membrane in a cylinder with 6mm in diameter using the
device software’s segmentation algorithm.
All measurements were performed by one of three experienced
operators. The computationally generated segmentation lines were
reviewed by the operators and manually corrected in cases of errors.
Visually Evoked Potentials
VEPs were recorded from Oz electrode against a Cz reference
electrode following checkerboard stimulation. Between 40 and 80
recordings were averaged twice until clear peaks became visible.
The latencies of the P100 peaks were used for analysis. Responses
of P100 above 119 ms were defined as abnormal.
Statistical methods
AMann-Whitney U-test was used to identify statistical differences
of age between the study cohorts. Spearman’s Rho tests were used
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for cross-correlation analysis of the clinical parameters (SARA
score, disease duration and number of repeats) within the SCA1
cohort.
Statistical differences between SCA1 patients and the group of
healthy controls were calculated using General Estimation
Equation (GEE) models to account for within-subject inter-eye
dependencies. The multiple tests of all sectors from all retinal
layers were adjusted using Bonferroni-Holm Correction. Correla-
tion analysis of a clinical parameter (SARA score, disease duration
and visual acuity) to the OCT data (RNFLT and macular
volumes) were equally performed with GEE. In all GEEs, OCT
measurements were included as the dependent variable.
All statistical analyses and graphical representations were
performed with R (R version 2.12.1) including the packages
geepack for calculating GEE, psych, Hmisc for basic statistics and
plotrix and gplots for graphic generation. All results from R were
validated using SPSS 18 (SPSS, Chicago, IL, USA). Graphical
presentations were prepared using Adobe Illustrator CS5 (Adobe
Systems, Munich, Germany).
Results
Cohort Description
In this study, we included nine patients with a genetically
diagnosed SCA1 and compared them to a gender- and age-
matched cohort of nine healthy controls. Demographic param-
eters of the investigated cohorts and the clinical results of the
SARA score, VEP, visual acuity, refractive error and the
number of repeats in the polyglutamine trace of the ATXN1
alleles are summarized in table 1. Due to the small sample size
and the pilot character of this study, an additional overview with
single patient profiles is given in table 2. The difference in age
between the groups was not significant (Mann-Whitney U test,
p = 0.93).
SARA scores for SCA1 patients ranged from 5 to 28 with a
median of 15 and the mean disease duration was 13.1 years,
ranging from 3 to 30 years. A general tendency towards higher
SARA scores for longer disease duration was visible (figure 3A) but
did not reach a significant level for the correlation (Spearman’s
Rho= 0.64, p = 0.061). Seven SCA1 patients provided trinucleo-
tide repeat numbers of the glutamine encoding part of the diseased
ATXN1 allele (mean= 48.1, SD=2.9) and, in addition, six of the
patients could provide the repeat numbers of the unaffected allele
(mean=30.7, SD=1.8).
Refractive error of patients (mean=20.68D, SD=1.33D,
Range=22.90 – 1.84D) and healthy controls (mean= 0.19D,
SD=1.50D, Range=21.67 – 3.95D) did not differ significantly
(GEE: p= 0.20). One patient and the corresponding healthy
control had to be excluded due to high refractive error.
The visual acuity of SCA1 patients (mean= 0.54, SD=0.32)
was significantly reduced (GEE: p= 0.003) compared to healthy
controls (0.86, SD=0.17).
Optical coherence tomography
All study subjects (n = 18) underwent an OCT examination for
both eyes (36 eyes). For RNFLT, two eyes from SCA1 patients
were excluded from further analysis: one right eye due to bad
image quality and one left eye due to blindness (post operation of
eye tumor). RNFLT was separated as depicted in figure 1C. The
total average RNFLT (G) of SCA1 patients was significantly
reduced compared to healthy controls (84.0612.7 mm vs.
97.267.7 mm, GEE: p= 0.004). RNFL thinning was predominant
and significant in temporal sectors (TS: p = 0.005, T: p,0.001, TI:
p,0.001) and was not found in nasal sectors (NS: p = 0.480, N:
Figure 1. Differences of RNFLT between SCA1 and HC. (A)
Average RNFLT (in mm) of the total ring scan (G) and in the different
sectors (nasal-superior (NS), nasal (N), nasal-inferior (NI), temporal-inferior
(TI), temporal (T) and temporal-superior (TS)). Error bars indicate standard
deviation. Significance levels (*** for p,0.001, ** for p,0.01 and * for
p,0.05) were calculated by GEE. (B) Mean RNFLT profile of both study
groups in mm. (C) Both eyes (OD= right, OS= left) of a sample patient
(upper line) with typical RNFLT sectors in comparison with matched
healthy control (bottom line). The colors of the sectors are related to the
comparison with the Spectralis normative database. Green indicates
thickness values within the 95%-percentile of the database, while sectors
in yellow were thinner than the 5%-percentile of the normative database
and sectors in red were within the lowest 1%.
doi:10.1371/journal.pone.0023024.g001
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p= 0.207, NI: p = 0.285) (figure 1A). The most pronounced
thinning was found in the temporal-inferior and temporal sectors.
When comparing the complete RNFLT profile of both study
cohorts (figure 1B), the regional degeneration of the temporal
retinal nerve fiber layer became apparent.
The Spectralis device provided a normative database that was
used to compare the individual results of the RNFLT sectors to a
large cohort of healthy controls. RNFL thickness below 5% of the
normative database controls was colored in yellow, while sectors in
red indicated values in the 1%-percentile. The normal range of
RNFLT values was defined as the 95%-percentile and was colored
in green (figure 1C gives an example). Two patients did not have
any sectors below the 5%-border while the rest exhibited at least
one sector below the normal range. Three patients showed
RNFLT values below 1% of the normative database for one or
more sectors. Table 3 summarized the occurrence of classifications
for the different sectors. In contrast, only a single sector of one
healthy control was in the 5%-percentile.
The mean thickness profiles of the additional retinal layers for
both study cohorts are shown in figure 2B. None of the additional
layers revealed apparent differences between the groups. When
averaging all layer profiles in sectors (data not shown), only the
Figure 2. Segmentation of retinal layers. (A) Sample ring scan with additional layer segmentation. Layers from top: Nerve fiber layer (NFL),
ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), photoreceptor
layer (PRL) and retinal pigment epithelium (RPE). (B) Comparison of the mean thickness of the additional retinal layers between healthy controls (in
blue) and SCA1 patients (in red).
doi:10.1371/journal.pone.0023024.g002
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thickness of the NS sector of the ganglion cell and inner plexiform
layer showed a reduction in SCA1 patients (GEE: p= 0.001).
Some patients with a distinct nystagmus or uncontrolled head
movements were not able to complete the more demanding
macular volume scans. Therefore, only 11 eyes of the SCA1
cohort could be analyzed. One TMV measurement of a healthy
control had to be excluded due to an erroneous scan. Thus,
only the related subjects from the matched group of healthy
controls were considered for the cohort comparison. SCA1
patients showed a not significant reduction of the TMV (SCA1:
mean = 8.2 mm3 (SD= 0.7 mm3) vs. HC: mean = 8.6 mm3
(SD= 0.4 mm3), GEE: p = 0.15) (table 4).
VEP
For 11 eyes from 6 SCA1 patients VEPs could be acquired in
sufficient quality and compared to VEPs of the corresponding healthy
controls. None of the participants showed a pathologic increase in
latency of the P100 peak and no significant difference between the
cohorts was detected (SCA1: mean=102.9 ms (SD=5.6 ms) vs. HC:
mean=102.4 ms (SD=3.3 ms), GEE: p=0.69).
Correlation of RNFLT with disease duration,SARA score
and visual acuity
Next, OCT findings were correlated with disease duration and
disease severity measured by SARA score. When comparing
Table 1. Demographic information and clinical of the patient cohort (SCA1) and the matched healthy controls group (HC).
SCA1 HC
Subjects N 9 9
Gender Male (%) 5 (56%) 5 (56%)
Female (%) 4 (44%) 4 (44%)
Age Mean (SD) 51.7 (8.8) 50.7 (8.7)
Range 39.0 – 67.0 38.0 – 66.0
Disease duration [in years] Mean (SD) 13.1 (8.3) N/A
Range 3.0 – 30.0 N/A
SARA score Median (SD) 15.0 (7.4) N/A
Range 5.0 – 28.0 N/A
CAG repeats (diseased allele) [number of repeats] Mean (SD) 48.1 (2.9) N/A
Range 45 – 53 N/A
CAG repeats (healthy allele) [number of repeats] Mean (SD) 30.7 (1.8) N/A
Range 28 – 33 N/A
Refractive error [D] Mean (SD) 20.68 (1.33) 0.19 (1.50)
Range 22.90 – 1.84 21.67 – 3.95
Visual acuity [decimal] Mean (SD) 0.54 (0.32) 0.86 (0.17)
Range 0.13 – 1.20 0.62 – 1.11
VEP P100 latency [ms] Mean (SD) 102.9 (5.6) 102.4 (3.3)
Range 94.3 – 111.0 98.0 – 109.0
Results for the VEP examination were available for 6 SCA1 patients and of 5 of the matching healthy controls. For 1 SCA1 patients repeat length of the diseased allele
were missing and 2 patients lack values for the healthy allele and 1 patient had no examination of the visual acuity.
doi:10.1371/journal.pone.0023024.t001
Table 2. Single case reports of SCA1 patients.
Case No. Clinical findings VEP (OD,OS) OCT examination (OD, OS)
SARA
score
Disease
duration
Repeats
(diseased
allele) P100 G NS N NI TI T TS TMV
1 5 3 50 104.3, 98.0 83, 85 82, 106 55, 72 93, 106 119, 100 69, 57 118, 112 8.28, 8.25
2 28 30 N/A 106.8, 111.3 66, 68 60, 86 43, 49 63, 65 106, 83 62, 58 90, 97 7.11, 6.97
3 11.5 4 N/A N/A, N/A N/A, 80 N/A, 67 N/A, 72 N/A, 84 N/A, 119 N/A, 62 N/A, 105 8.90, 8.76
4 26 16 47 N/A, N/A 60, 77 90, 115 44, 62 88, 89 55, 68 44, 55 68, 108 N/A, N/A
5 21 12 53 N/A, N/A 87, 84 84, 78 72, 74 86, 91 125, 125 69, 58 118, 114 N/A, N/A
6 13 19 49 99.3, 99.3 96, 97 86, 118 87, 84 122, 129 142, 138 64, 59 114, 109 8.95, 8.99
7 15 8 48 109.3, N/A 92, N/A 97, N/A 78, N/A 128, N/A 97, N/A 61, N/A 131, N/A 7.69, N/A
8 18 10 45 108.0, 103.8 106, 101 128, 113 77, 70 112, 138 141, 133 78, 70 160, 146 8.46, 8.48
9 12.5 16 45 97.5, 94.3 83, 79 76, 75 61, 54 80, 70 131, 126 65, 66 127, 123 8.63, 8.64
doi:10.1371/journal.pone.0023024.t002
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RNFLT (G) with SARA score and disease duration, GEEs for
both were not significant (SARA: p= 0.073, duration: p = 0.098).
Scatter plots of RNFLT with SARA score and disease duration are
given in figures 3B and 3C, respectively, proposing a possible trend
for a correlation of RNFLT with SARA score.
Figure 3D show the correlation of the visual acuity with RNFLT
(G) for SCA1 patients (red) and healthy controls (blue) with no
significant correlations between the combined cohorts (GEE:
p= 0.46).
Discussion
This is the first study investigating retinal involvement in SCA1
patients using optical coherence tomography. We found a pattern
of temporal atrophy of the retinal nerve fiber layer in most
patients. Layer segmentation analysis confirmed temporal RNFLT
reduction whereas no significant differences were seen in average
of ganglion cell layer, inner and outer plexiform layer, photore-
ceptor layer and pigment epithelium. In sector analysis of layers
only the NS sector of the ganglion cell and inner plexiform layer
showed a reduction in SCA1 patients. Two patients (table 2, cases
6 and 8) displayed no significant RNFLT changes. The patient
with longest disease duration (30 years; table 2, case no. 2) and
highest SARA score (28) showed additional severe macular
Figure 3. Correlation of clinical parameters with RNFLT. (A) Dependency of disease duration to SARA score. RNFLT with respect to SARA score
(B), disease duration (C) and visual acuity (D) for SCA1 patients (red) and healthy controls (blue).
doi:10.1371/journal.pone.0023024.g003
Table 3. Comparison of RNFLT results to the Spectralis
normative Database.
SCA1 HC
Total average RNFLT (G) [mm] N eyes classified ,5% 6 0
N eyes classified ,1% 3 0
RNFLT Nasal-Superior (NS) [mm] N eyes classified ,5% 2 1
N eyes classified ,1% 1 0
RNFLT Nasal (N) [mm] N eyes classified ,5% 2 0
N eyes classified ,1% 0 0
RNFLT Nasal-Inferior (NI) [mm] N eyes classified ,5% 2 0
N eyes classified ,1% 0 0
RNFLT Temporal-Inferior (TI) [mm] N eyes classified ,5% 6 0
N eyes classified ,1% 4 0
RNFLT Temporal (T) [mm] N eyes classified ,5% 2 0
N eyes classified ,1% 1 0
RNFLT Temporal-Superior (TS) [mm] N eyes classified ,5% 4 0
N eyes classified ,1% 2 0
doi:10.1371/journal.pone.0023024.t003
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atrophy. However, in this patient RNFLT reduction was very
prominent, indicating that in late stage disease nerve fiber atrophy
could lead to ganglion cell degeneration and consecutively to
macular volume reduction. Although a reduction of retinal nerve
fiber layer thickness was not present in each individual SCA1
patient, a correlation trend of RNFLT with disease duration and
severity was seen. In contrast to OCT, VEP P100 latencies were
not able to detect changes in our patients. However, since VEP
amplitudes correlate better with axonal loss but were not
analyzable in our small sample size due to high inter- and intra-
subject variability, we might have missed a significant difference,
which might be shown in a larger cohort.
Strengths of the study are the prospective design, the matched
control group and the use of spectral domain OCT with layer
segmentation analysis. The used OCT device provides an eye
tracking function that registers OCT scans to a fundus image and
thereby reduces the effects of eye movement during scans. This
function makes the application of OCT examination and
especially of 3D volume scans possible for patients with severe
head ataxia or eye movement abnormalities. However, in several
patients this correction was not sufficient, leading to missing scans
in the demanding macular volume scans. Another weakness of the
study is the low sample size which is owed to the rarity of the
disease and the severe disability of many patients. Most likely this
contributed to not significant changes to macular volumes and
correlations to SARA score or disease duration.
Interestingly, the consistent pattern of selective temporal
RNFLT reduction in our study prompts the question of
pathophysiologic relevance. One explanation could be that
RNFLT analysis enables early detection of incipient optic atrophy
in SCA1 since a temporal emphasis of RNFLT reduction is found
in a variety of diseases associated with optic nerve atrophy. These
conditions comprise post neuritic optic atrophy in multiple
sclerosis [16][20], hereditary optic atrophies such as dominant
optic atrophy (DOA) and Leber’s hereditary optic neuropathy
(LHON) and toxic optic atrophies. However VEP did not detect
optic atrophy in our study with all the drawbacks discussed above.
But also previous studies using VEP did not find optic nerve
involvement to such an extent as our results would suggest [9][10].
Selective temporal RNFLT involvement could be explained
pathophysiologically by a differential vulnerability of retinal axons
to mutated ataxin1.The temporal quadrant of the retinal nerve
fiber layer is built primarily by parvo-cellular axons from the
papillo-macular bundle. These fibers consist of smaller, thinly
myelinated axons with rapid firing rates which serve the visual
functions of high resolution visual acuity, color vision and high
spatial frequency of contrast sensitivity. On the other hand,
magno-cellular ganglion cell axons and photoreceptors which are
both distributed evenly throughout the retina seem relatively
unaffected from damage. Magno-cellular ganglion cells have
thicker axons with lower firing rate and serve low-spatial-
frequency contrast sensitivity and motion stereopsis.
Other diseases with primary involvement of parvocellular axons
comprise the so called non-syndromic mitochondrial optic
neuropathies such as Leber’s hereditary optic neuropathy (LHON)
and OPA1 related dominant optic nerve atrophy (DOA) and toxic
and nutritional optic neuropathies such as tobacco-alcohol
amblyopia or ethambutol-induced optic neuropathy [21].
As common etiologic pathway of such disparate diseases the
disruption of mechanisms participating in the correction of
oxidative stress with primary insult to mitochondria is discussed
[21][22]. Due to their small volume and fast firing response,
parvo-cellular axons may be more susceptible to energy depletion
by defective oxidative phosphorylation resulting from vitamin
depletion or mutations affecting mitochondrial function.
In SCA1, nuclear and cytosolic protein aggregates are
associated with neurodegeneration of cerebellar Purkinje neurons.
Although many protein interaction partners of ataxin1 have been
Table 4. OCT examination results.
SCA1 HC GEE
P value Estimate Std. err.
Total average RNFLT (G) [mm] Mean (SD) 84.0 (12.7) 97.2 (7.7) 0.00386 213.0 4.50
Range 60.0–106.0 87.0–113.0
RNFLT Nasal-Superior (NS) [mm] Mean (SD) 91.3 (19.6) 95.6 (18.0) 0.480 24.5 6.32
Range 60.0–128.0 69.0–134.0
RNFLT Nasal (N) [mm] Median (SD) 65.9 (13.7) 72.4 (13.0) 0.207 26.37 5.04
Range 43.0–87.0 45.0–103.0
RNFLT Nasal-Inferior (NI) [mm] Mean (SD) 96.5 (23.5) 106.4 (14.4) 0.285 29.20 8.60
Range 63.0–138.0 78.0–129.0
RNFLT Temporal-Inferior (TI) [mm] Mean (SD) 113.0 (26.1) 147.9 (13.7) 0.00007 235.4 8.86
Range 55.0–142.0 120.0–176.0
RNFLT Temporal (T) [mm] Median (SD) 62.3 (7.7) 74.1 (9.2) 0.00072 211.8 3.48
Range 44.0–78.0 61.0–90.0
RNFLT Temporal-Superior (TS) [mm] Mean (SD) 115.0 (21.3) 134.5 (9.9) 0.0052 219.8 6.90
Range 68.0–160.0 119.0–150.0
Total macular volume (TMV) [mm3] Mean (SD) 8.2 (0.7) 8.6 (0.4) 0.146 20.458 0.315
Range 7.0 – 9.0 8.0–9.1
RNFLT results were obtained from 9 SCA1 and compared to 9 age/sex matched healthy controls (HC). 2 eyes of SCA1 patients had to be excluded, one left eye due to
blindness and one right eye because of errors in the OCT image. In total, 11 eyes of SCA1 patients fulfilled quality criteria for the TMV scan and were compared to the
corresponding eyes of the matching healthy controls.
doi:10.1371/journal.pone.0023024.t004
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identified and its impact on transcriptional dysregulation has been
stated, the clear pathophysiologic processes leading to cell death
remain to be elucidated [3]. Few hints point towards impeded
antioxidant mechanisms such as reduced Cu/ZnSOD dismutase
activity with subsequent accumulation of reactive oxygen species
in the disease process [23]. Hypothetically the patchy pattern of
temporal RNFLT reduction seen in our patients could be caused
by localised breakdown of oxidative defense mechanisms.
In terms of retinal damage other previously examined ataxia
disorders such as Friedreich’s ataxia and neuropathy ataxia
retinitis pigmentosa (NARP) belonging to the group of syndromic
mitochondriopathies present with more general retinal thinning
[24][25]. One explanation could be the disruption of complex I, II
and III as compared to only complex I in the non-syndromic
mitochondrial neuropathies [22]. However, the role of respiratory
chain complexes in SCA1 is not clear yet.
In SCA7, along with a peripheral RNFLT reduction even a
sparing of the temporal sector has been observed in RNFLT
measurements resembling the pattern in other retinal dystrophies
such as retinitis pigmentosa [26]. Key to understanding the
complementary findings could be the diverse function of ataxin 1
and ataxin7. In SCA7 a pronounced retinal cone-rod dystrophy
associated with visual loss is a characteristic feature especially in
early disease stages. Additionally in late stage disease a
maculopathy can evolve (‘bull’s eye’ maculopathy) [27]. In
transgenic mice it has been shown that ataxin 7 can suppress a
cone-rod homebox protein transactivation in retinal photoreceptor
cells thus controlling expression level of several photoreceptor-
specific genes such as rhodopsin [28]. The relative sparing of the
temporal sector has been discussed as possible result of the relative
sparing of the inner macula around the central fovea associated
with normal ganglion cell layer thickness of the peripapillary
temporal quadrant in earlier disease stage [6].
These distinct patterns raise the question whether OCT may
serve a purpose in differential diagnosis in ataxia disorders, a topic
yet to be addressed by examination of larger patient cohorts
composed of different ataxia disorders in direct comparison.
Additionally larger studies should allow more precise layer
segmentation analysis. A longitudinal study design could also
serve to evaluate potential use of RNFLT as non invasive disease
progression marker.
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